drugset / Trial / NCT00554723

CHInese Medicine NeuroAid Efficacy on Stroke Recovery

NCT00554723 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

CHIMES is a double blind, placebo controlled, randomized, multicenter study to test the hypothesis that NeuroAid is superior to placebo in reducing neurological deficit and improving functional outcome in patients with cerebral infarction of an intermediate range of severity.

Timeline

Start
2007-05
Primary completion
2012-08
Completion
2012-08

Outcome

Missed primary endpoint

paper MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. PMID 23780952 ↗

paper The modified Rankin Scale shift analysis-adjusted odds ratio was 1.09 (95% confidence interval, 0.86-1.32). PMID 23780952 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject NeuroAiD Traditional medicine (herbal / TCM) — Oral

Indications